A synthetic fibrin cross-linking polymer for modulating clot properties and inducing hemostasis

Science Translational Medicine

Volumn 7, Issue 277, 2015, Pages

  Chan, Leslie W ^a   Wang, Xu ^b   Wei, Hua ^a   Pozzo, Lilo D ^c   White, Nathan J ^b   Pun, Suzie H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENGINEERED HEMOSTATIC POLYMER; FIBRIN; PLASMIN; POLYMER; UNCLASSIFIED DRUG; CROSS LINKING REAGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTICLE; BINDING SITE; BIOENGINEERING; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; CROSS LINKING; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME DEGRADATION; FEMORAL ARTERY; FEMORAL ARTERY INJURY; FIBRIN POLYMERIZATION; FIBRINOLYSIS; FLUID RESUSCITATION; GEL PERMEATION CHROMATOGRAPHY; HEMOSTASIS; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY FUNCTION; LIVER FUNCTION; MOLECULAR WEIGHT; NONHUMAN; ONCOTIC PRESSURE; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; SURVIVAL RATE; THROMBOELASTOGRAPHY; TISSUE PERFUSION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HUMAN; INJURIES; KINETICS; PATHOLOGY; POLYMERIZATION; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; BLOOD COAGULATION; CROSS-LINKING REAGENTS; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; FIBRIN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; KINETICS; POLYMERIZATION; POLYMERS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84929009119     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010383     Document Type: Article

References (39)

1. A. Sauaia, F. A. Moore, E. E. Moore, K. S. Moser, R. Brennan, R. A. Read, P. T. Pons, Epidemiology of trauma deaths: A reassessment. J. Trauma 38, 185-193 (1995).
2. R. Davenport, J. Manson, H. De'Ath, S. Platton, A. Coates, S. Allard, D. Hart, R. Pearse, K. J. Pasi, P. MacCallum, S. Stanworth, K. Brohi, Functional definition and characterization of acute traumatic coagulopathy. Crit. Care Med. 39, 2652-2658 (2011).
3. K. Brohi, J. Singh, M. Heron, T. Coats, Acute traumatic coagulopathy. J. Trauma 54, 1127-1130 (2003).
4. I. Raza, R. Davenport, C. Rourke, S. Platton, J. Manson, C. Spoors, S. Khan, H. D. De'Ath, S. Allard, D. P. Hart, K. J. Pasi, B. J. Hunt, S. Stanworth, P. K. MacCallum, K. Brohi, The incidence and magnitude of fibrinolytic activation in trauma patients. J. Thromb. Haemost. 11, 307-314 (2013).
5. H. E. Achneck, B. Sileshi, R. M. Jamiolkowski, D. M. Albala, M. L. Shapiro, J. H. Lawson, A comprehensive review of topical hemostatic agents: Efficacy and recommendations for use. Ann. Surg. 251, 217-228 (2010).
6. B. J. Hunt, Bleeding and coagulopathies in critical care. N. Engl. J. Med. 370, 847-859 (2014).
7. F. A. Moore, E. E. Moore, A. Sauaia, Blood transfusion. An independent risk factor for post-injury multiple organ failure. Arch. Surg. 132, 620-625 (1997).
8. J. P. Bertram, C. A. Williams, R. Robinson, S. S. Segal, N. T. Flynn, E. B. Lavik, Intravenous hemostat: Nanotechnology to halt bleeding. Sci. Transl. Med. 1, 11ra22 (2009).
9. T. Nishiya, M. Murata, M. Handa, Y. Ikeda, Targeting of liposomes carrying recombinant fragments of platelet membrane glycoprotein Iba to immobilized von Willebrand factor under flow conditions. Biochem. Biophys. Res. Commun. 270, 755-760 (2000).
10. C. L. Modery, M. Ravikumar, T. L. Wong, M. J. Dzuricky, N. Durongkaveroj, A. Sen Gupta, Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery. Biomaterials 32, 9504-9514 (2011).
11. M. Ravikumar, C. L. Modery, T. L. Wong, M. Dzuricky, A. P. D. Sen Gupta, Mimicking adhesive functionalities of blood platelets using ligand-decorated liposomes. Bioconjug. Chem. 23, 1266-1275 (2012).
12. Y. Okamura, S. Takeoka, K. Eto, I. Maekawa, T. Fujie, H. Maruyama, Y. Ikeda, M. Handa, Development of fibrinogen g-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. J. Thromb. Haemost. 7, 470-477 (2009).
13. S. W. Jones, R. A. Roberts, G. R. Robbins, J. L. Perry, M. P. Kai, K. Chen, T. Bo, M. E. Napier, J. P. Ting, J. M. Desimone, J. E. Bear, Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. J. Clin. Invest. 123, 3061-3073 (2013).
14. I. N. Chernysh, C. Nagaswami, P. K. Purohit, J. W. Weisel, Fibrin clots are equilibrium polymers that can be remodeled without proteolytic digestion. Sci. Rep. 2, 879 (2012).
15. O. M. Theusinger, W. Baulig, L. M. Asmis, B. Seifert, D. R. Spahn, In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM®). Thromb. Haemost. 104, 385-391 (2010).
16. E. L. Hethershaw, A. L. Cilia La Corte, C. Duval, M. Ali, P. J. Grant, R. A. Ariëns, H. Philippou, The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J. Thromb. Haemost. 12, 197-205 (2014).
17. A. F. Kolodziej, S. A. Nair, P. Graham, T. J. McMurry, R. C. Ladner, C. Wescott, D. J. Sexton, P. Caravan, Fibrin specific peptides derived by phage display: Characterization of peptides and conjugates for imaging. Bioconjug. Chem. 23, 548-556 (2012).
18. A. F. Kolodziej, Z. Zhang, K. Overoye-Chan, V. Jacques, P. Caravan, Peptide optimization and conjugation strategies in the development of molecularly targeted magnetic resonance imaging contrast agents. Methods Mol. Biol. 1088, 185-211 (2014).
19. G. D. Barrett, I. J. Constable, A. D. Stewart, Clinical results of hydrogel lens implantation. J. Cataract Refract. Surg. 12, 623-631 (1986).
20. R. Duncan, The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347-360 (2003).
21. M. Mammen, S.-K. Choi, G. M. Whitesides, Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. 37 (1998).
22. M. E. Carr Jr., J. Hermans, Size and density of fibrin fibers from turbidity. Macromolecules 11, 46-50 (1978).
23. J. S. Hagemo, J. J. Jørgensen, S. R. Ostrowski, A. Holtan, Y. Gundersen, P. I. Johansson, P. A. Næss, C. Gaarder, Changes in fibrinogen availability and utilization in an animal model of traumatic coagulopathy. Scand. J. Trauma Resusc. Emerg. Med. 21, 56 (2013).
24. D. Fries, W. Z. Martini, Role of fibrinogen in trauma-induced coagulopathy. Br. J. Anaesth. 105, 116-121 (2010).
25. G. F. Grannis, Plasma fibrinogen: Determination, normal values, physiopathologic shifts, and fluctuations. Clin. Chem. 16, 486-494 (1970).
26. S. Finfer, R. Bellomo, N. Boyce, J. French, J. Myburgh, R. Norton; SAFE Study Investigators, A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N. Engl. J. Med. 350, 2247-2256 (2004).
27. D. N. Darlington, T. Craig, M. D. Gonzales, M. G. Schwacha, A. P. Cap, M. A. Dubick, Acute coagulopathy of trauma in the rat. Shock 39, 440-446 (2013).
28. S. R. Odom, M. D. Howell, G. S. Silva, V. M. Nielsen, A. Gupta, N. I. Shapiro, D. Talmor, Lactate clearance as a predictor of mortality in trauma patients. J. Trauma Acute Care Surg. 74, 999-1004 (2013).
29. T. Yamaoka, Y. Tabata, Y. Ikada, Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83, 601-606 (1994).
30. J. W. Weisel, R. I. Litvinov, Mechanisms of fibrin polymerization and clinical implications. Blood 121, 1712-1719 (2013).
31. K. Overoye-Chan, S. Koerner, R. J. Looby, A. F. Kolodziej, S. G. Zech, Q. Deng, J. M. Chasse, T. J. McMurry, P. Caravan, EP-2104R: A fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. J. Am. Chem. Soc. 130, 6025-6039 (2008).
32. J. Vymazal, E. Spuentrup, G. Cardenas-Molina, A. J. Wiethoff, M. G. Hartmann, P. Caravan, E. C. Parsons Jr., Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: Results of a phase II clinical study of feasibility. Invest. Radiol. 44, 697-704 (2009).
33. H. Schöchl, C. J. Schlimp, Trauma bleeding management: The concept of goal-directed primary care. Anesth. Analg. 119, 1064-1073 (2014).
34. M. A. Schreiber, Coagulopathy in the trauma patient. Curr. Opin. Crit. Care 11, 590-597 (2005).
35. M. A. Dobrovolskaia, P. Aggarwal, J. B. Hall, S. E. McNeil, Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5, 487-495 (2008).
36. M. Swaroop, D. C. Straus, O. Agubuzu, T. J. Esposito, C. R. Schermer, M. L. Crandall, Pre-hospital transport times and survival for Hypotensive patients with penetrating thoracic trauma. J. Emerg. Trauma Shock 6, 16-20 (2013).
37. K. Brohi, M. J. Cohen, R. A. Davenport, Acute coagulopathy of trauma: Mechanism, identification and effect. Curr. Opin. Crit. Care 13, 680-685 (2007).
38. M. J. Yanjarappa, K. V Gujraty, A. Joshi, A. Saraph, R. S. Kane, Synthesis of copolymers containing an active ester of methacrylic acid by RAFT: Controlled molecular weight scaffolds for biofunctionalization. Biomacromolecules 7, 1665-1670 (2006).
39. M. E. Carr Jr., C. L. Hardin, Fibrin has larger pores when formed in the presence of erythro-cytes. Am. J. Physiol. 253, H1069-H1073 (1987).